10,581
Total Claims
$1.8M
Drug Cost
699
Beneficiaries
$2,611
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+85%
Cost per patient vs peers
$2,611 vs $1,411 avg
+51%
Brand preference vs peers
16.0% vs 10.6% avg
Brand vs Generic
84% generic
Brand: 1,678 claims · $1.6M
Generic: 8,801 claims · $211K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 180 | $251K |
| Rivaroxaban | 144 | $201K |
| Empagliflozin | 117 | $166K |
| Sacubitril/Valsartan | 96 | $135K |
| Sitagliptin Phosphate | 101 | $132K |
| Linagliptin | 64 | $87K |
| Sitagliptin Phos/Metformin Hcl | 55 | $67K |
| Dapagliflozin Propanediol | 30 | $45K |
| Dulaglutide | 14 | $42K |
| Linaclotide | 36 | $34K |
| Insulin Glargine,hum.Rec.Anlog | 45 | $29K |
| Semaglutide | 12 | $28K |
| Insulin Aspart | 30 | $24K |
| Sitagliptin Phos/Metformin Hcl | 15 | $22K |
| Insulin Lispro | 16 | $22K |
Prescribing Profile
Patient Profile
73
Avg Age
57%
Female
1.52
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data